Literature DB >> 21667128

Mouse models of diseases of megakaryocyte and platelet homeostasis.

Catherine L Carmichael1, Warren S Alexander.   

Abstract

Platelets are the small anuclear blood cells that are the product of megakaryocytopoiesis, the process of hematopoietic stem cell commitment to megakaryocyte production and the differentiation and maturation of these cells for platelet release. Deregulation or disruption of megakaryocytopoiesis can result in platelet deficiencies, the thrombocytopenias, with attendant risk of hemorrhage or thrombocytosis, a pathological excess of platelet numbers. Mouse models, particularly those engineered to carry genetic alterations modeling mutations associated with human disease, have provided important insights into megakaryocytopoiesis and deregulation of this process in disease. This review focuses on mouse models of diseases of altered megakaryocyte and platelet number, illustrating the profound contribution of these models in validating suspected roles of disease-associated genetic alterations, promoting discovery of new links between genetic mutations and specific diseases, and providing unique tools for better understanding of disease pathophysiology and progression, as well as resources to define drug action or develop new therapeutic strategies.

Entities:  

Mesh:

Year:  2011        PMID: 21667128     DOI: 10.1007/s00335-011-9336-4

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  157 in total

1.  The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation.

Authors:  E Haddad; E Cramer; C Rivière; P Rameau; F Louache; J Guichard; D L Nelson; A Fischer; W Vainchenker; N Debili
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

2.  A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.

Authors:  Ian J Majewski; Donald Metcalf; Lisa A Mielke; Danielle L Krebs; Sarah Ellis; Marina R Carpinelli; Sandra Mifsud; Ladina Di Rago; Jason Corbin; Nicos A Nicola; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

3.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 4.  Thrombocytosis.

Authors:  Radek C Skoda
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

5.  Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.

Authors:  Oliver Tunstall-Pedoe; Anindita Roy; Anastasios Karadimitris; Josu de la Fuente; Nicholas M Fisk; Phillip Bennett; Alice Norton; Paresh Vyas; Irene Roberts
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

6.  Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.

Authors:  Shu Xing; Tina Ho Wanting; Wanming Zhao; Junfeng Ma; Shaofeng Wang; Xuesong Xu; Qingshan Li; Xueqi Fu; Mingjiang Xu; Zhizhuang Joe Zhao
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

7.  Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Wei Tong
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

10.  Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.

Authors:  T R Ulich; J del Castillo; S Yin; S Swift; D Padilla; G Senaldi; L Bennett; J Shutter; J Bogenberger; D Sun
Journal:  Blood       Date:  1995-08-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.